Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Ability Pharma (abilitypharma.es) is a clinical-stage biopharmaceutical company headquartered in Barcelona, Spain. It focuses primarily on developing innovative anti-cancer drugs based on autophagy mechanisms, advancing its pipeline development for multiple high-mortality cancers with unmet clinical needs including pancreatic cancer, lung cancer, and endometrial cancer. The website fully displays the company's background, R&D pipeline, clinical trial progress, investor information, and corporate governance content.
The company's lead candidate drug ABTL0812 (granted the INN name IBRILATAZAR by the WHO) is a first-in-class oral targeted drug. It induces selective autophagic apoptosis in cancer cells by activating PPAR receptors and blocking the PI3K/Akt/mTOR pathway. Currently, the 2b-phase clinical trial of this drug for metastatic pancreatic cancer has completed patient recruitment across multiple countries, and the 2a-phase clinical trials for lung squamous cell carcinoma and endometrial cancer have yielded positive results. It has also received orphan drug designation from the FDA and EMA for pediatric neuroblastoma. The website regularly updates clinical trial progress, financing updates, and industry news, with a relatively high level of information transparency.
Pros: Ability Pharma focuses on unmet needs for hard-to-treat cancers, with an innovative R&D mechanism. Early clinical data has demonstrated good safety profile. The management team has extensive experience in drug regulation and approval in Europe and North America, and its R&D collaboration network covers the world's top oncology research institutions.
Cons: The core drug has not yet been launched, so there is inherent risk of R&D failure. The company does not provide services directly to general patients, and there is no Chinese localization support.
The website is currently directly accessible via the public Internet in China and loads normally. It is suitable for Chinese pharmaceutical industry practitioners, biopharmaceutical investors, and R&D collaborators to visit for information.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on abilitypharma.es official site.
abilitypharma.es is an Spain Health provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach abilitypharma.es directly.